Abstract: The present disclosure provides innovative methodology and related compositions and kits for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysyl oxidase-like proteins, an inhibitor of LOX and an inhibitor of a LOXL, or a synergistic combination of an inhibitor of LOX or LOXL combined with other therapeutic agents. Also provided are innovative methods for selecting agents that prevent or inhibit tumor invasion, angiogenesis and metastasis, by contacting cells that are in an epithelial-mesenchymal transition (EMT) state with a candidate agent and detecting a change in the EMT state of the cells. Methods and related compositions and kits for diagnosing or monitoring various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using molecules or agents that specifically recognize processed forms of LOX or LOXL are also provided.

Abstract: Disclosed herein are methods and compositions for increasing perfusion, reducing hypoxia, reducing permeability and increasing the integrity of vasculature; e.g., in a tumor. The compositions include inhibitors of the LOXL2 enzyme. In certain of the methods, a LOXL2 inhibitor is used in combination with, and facilitates the therapeutic activity of, an anti-neoplastic agent.

Abstract: Provided are methodology, compositions and kits to prevent and treat diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using processed lysyl oxidase or lysyl oxidase-like protein inhibitors, LOX inhibitors and LOXL inhibitors, or synergistic combinations of such inhibitors with therapeutic agents. Provided are methods for selecting tumor invasion, angiogenesis and metastasis inhibiting agents, by contacting cells in EMT states with candidate agents and detecting changes in such states; and methods, compositions, and kits for diagnosing or monitoring diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using molecules or agents specifically recognizing processed LOX or LOXL. Provided are methods, compositions, medical devices, systems and kits for preventing or treating diseases and conditions associated with fibrosis, including pathological cardiovascular conditions and diseases, e.g.

Abstract: The present disclosure provides methodology and compositions for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysyl oxidase-like proteins, an inhibitor of LOX or LOXL, or a synergistic combination thereof combined with other therapeutic agents. Methods and compositions for diagnosing or monitoring various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, are also provided. Also provided herein are methods and related compositions, medical devices, systems and kits for preventing or treating various diseases and conditions associated with fibrosis with compositions comprising inhibitors of LOX or LOXL.

Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.

Abstract: A product comprising at least one densified biomass particulate of a given mass having no added binder and comprised of a plurality of lignin-coated plant biomass fibers is provided, wherein the at least one densified biomass particulate has an intrinsic density substantially equivalent to a binder-containing densified biomass particulate of the same given mass and h a substantially smooth, non-flakey outer surface. Methods for using and making the product are also described.

Abstract: Provided are methodology, compositions and kits to prevent and treat diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using processed lysyl oxidase or lysyl oxidase-like protein inhibitors, LOX inhibitors and LOXL inhibitors, or synergistic combinations of such inhibitors with therapeutic agents. Provided are methods for selecting tumor invasion, angiogenesis and metastasis inhibiting agents, by contacting cells in EMT states with candidate agents and detecting changes in such states; and methods, compositions, and kits for diagnosing or monitoring diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using molecules or agents specifically recognizing processed LOX or LOXL. Provided are methods, compositions, medical devices, systems and kits for preventing or treating diseases and conditions associated with fibrosis, including pathological cardiovascular conditions and diseases, e.g.

Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.

Abstract: A tool setting or tool analysis device for a machine tool includes a light source for producing a light beam. A light receiver receives the light beam and produces a signal indicative of the amount of light received. This is analysed by a main analysis circuit to generate a trigger signal to a machine controller when the beam is at least partially occluded. To provide fail-safe operation should the main circuit not recognise the tool, a back-up trigger signal is produced after a delay by a delay circuit. In one preferred form, the back-up trigger signal may oscillate, providing repeated edges which can ensure fail-safe operation even if the machine controller suffers from a blind window and therefore misses the initial trigger signal.

Abstract: A product is provided comprising at least one densified biomass particulate having a substantially smooth, non-flakey outer surface and containing no added binder, wherein said densified biomass particulate is comprised of a plurality of pretreated lignin-coated plant biomass fibers which contain a trace amount of base from pretreatment of said fibers. Methods for using and making the product are also described.

Abstract: A tool setting or tool analysis device for a machine tool comprises a light source for producing a light beam. A light receiver receives the light beam and produces a signal indicative of the amount of light received. This is analyzed by a main analysis circuit to generate a trigger signal to a machine controller when the beam is at least partially occluded. To provide fail-safe operation should the main circuit not recognize the tool, a back-up trigger signal is produced after a delay by a delay circuit. In one preferred form, the back-up trigger signal may oscillate, providing repeated edges which can ensure fail-safe operation even if the machine controller suffers from a blind window and therefore misses the initial trigger signal.

Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.

Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.

Abstract: A product comprising at least one densified biomass particulate of a given mass having no added binder and comprised of a plurality of lignin-coated plant biomass fibers is provided, wherein the at least one densified biomass particulate has an intrinsic density substantially equivalent to a binder-containing densified biomass particulate of the same given mass and h a substantially smooth, non-flakey outer surface. Methods for using and making the product are also described.

Abstract: A method is described for calculating an optimum stand-off distance for surface position measurements to be acquired by a coordinate positioning apparatus including a measurement probe. The coordinate positioning apparatus may include a machine tool and the measurement probe may include a touch trigger probe having a deflectable stylus. The method includes the step of calculating an optimum stand-off distance using at least one measured acceleration characteristic of the coordinate positioning apparatus. In this manner, measurement cycle times may be optimised.

Abstract: Disclosed herein are methods for identifying inhibitors of the catalytic activity of LOXL2 using in vitro assays. In certain embodiments, inhibitors identified by these in vitro assays are effective in inhibiting tumor desmoplasia and fibrosis.

Abstract: Disclosed herein are methods for identifying inhibitors of LOXL2 activity using in vivo assays. The assays include, for example, CCL4-induced liver fibrosis, bleomycin-induced lung fibrosis, collagen-induced arthritis, tumor growth following surgical orthotopic implantation of cultured tumor cells, metastasis following intracardiac injection of cultured tumor cells, tumor xenograft models, and vasculogenesis and/or angiogenesis following implantation of exogenous basement membrane.

Abstract: Disclosed herein are methods and compositions for treatment of neovascularization, in particular, ocular neovascularization and resultant fibrotic damage. Compositions comprise inhibitors of the activity of one or more lysyl oxidase-type enzymes, and the methods include methods for making the inhibitors and methods for administration of the inhibitors to a subject in need thereof.

Abstract: A tool setting or tool analysis device for a machine tool comprises a light source for producing a light beam. A light receiver receives the light beam and produces a signal indicative of the amount of light received. This is analyzed by a main analysis circuit to generate a trigger signal to a machine controller when the beam is at least partially occluded. To provide fail-safe operation should the main circuit not recognize the tool, a back-up trigger signal is produced after a delay by a delay circuit. In one preferred form, the back-up trigger signal may oscillate, providing repeated edges which can ensure fail-safe operation even if the machine controller suffers from a blind window and therefore misses the initial trigger signal.

Abstract: The present disclosure provides innovative methodology and related compositions and kits for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysyl oxidase-like proteins, an inhibitor of LOX and an inhibitor of a LOXL, or a synergistic combination of an inhibitor of LOX or LOXL combined with other therapeutic agents. Also provided are innovative methods for selecting agents that prevent or inhibit tumor invasion, angiogenesis and metastasis, by contacting cells that are in an epithelial-mesenchymal transition (EMT) state with a candidate agent and detecting a change in the EMT state of the cells. Methods and related compositions and kits for diagnosing or monitoring various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using molecules or agents that specifically recognize processed forms of LOX or LOXL are also provided.